Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 3Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasm Metastasis 3Colorectal Neoplasms 3Neoplasms 2Colonic Neoplasms 2Pancreatic Neoplasms 1Lung Neoplasms 1Biliary Tract Neoplasms 1Advanced Solid Tumor 1

Interventions

Carboplatin 49Pemetrexed 38Cisplatin 34Radiotherapy 32Docetaxel 31Gemcitabine 25Paclitaxel 24Nivolumab 18pembrolizumab 15Etoposide 15Radiosurgery 13Erlotinib Hydrochloride 11Bevacizumab 11Magnetic Resonance Spectroscopy 10Vinorelbine 9Radiation 9Cyclophosphamide 7durvalumab 6Gefitinib 6Fluorodeoxyglucose F18 6Celecoxib 6atezolizumab 5Oxaliplatin 5Irinotecan 5Immunoglobulin G 5Drug Therapy 5Disulfides 5Dexamethasone 5Chemotherapy, Adjuvant 5vandetanib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lung Neoplasms × adagrasib × Clear all
NCT04975256 2024-12-16

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Mirati Therapeutics Inc.

Phase 1 Terminated
7 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡